drugset / Trial / NCT07645651
Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer
Phase 1
Not yet recruiting
15 enrolled
University of Washington
Carrick Therapeutics Limited · collabLopker Family Foundation · collabThe V Foundation for Cancer Research · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of samuraciclib in patients with localized pancreatic cancer.
Timeline
- Start
- 2026-10-01
- Primary completion
- 2027-07-14
- Completion
- 2027-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Samuraciclib | Unknown | — | Oral |